CureVac NV (CVAC)

Currency in USD
4.660
-0.010(-0.21%)
Closed·
Showing CureVac NV historical data. For real-time data please try another search
Fair Value
Day's Range
4.5704.665
52 wk Range
2.4755.720
Key Statistics
Prev. Close
4.66
Open
4.57
Day's Range
4.57-4.665
52 wk Range
2.475-5.72
Volume
1.15M
Average Vol. (3m)
1.12M
1-Year Change
-0.4274%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CVAC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Currently not supported.
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

CureVac NV News & Analysis

Show more

CureVac NV SWOT Analysis


Valuation Insights
Analysts set price targets ranging from $10 to $16, reflecting varied perspectives on CureVac's potential amid its pivotal year of clinical advancements and IP litigation outcomes
Catalysts on Horizon
Anticipate key milestones in 2025-2026, including GBM vaccine results and ExPEC IND filing, potentially reshaping CureVac's market position and investor sentiment
Financial Fortitude
With a robust cash position of €438 million funding operations into 2028, CureVac demonstrates financial stability amidst market challenges and ongoing clinical developments
mRNA Pioneer's Edge
CureVac's innovative mRNA platform underpins a diverse pipeline, including promising vaccine candidates for glioblastoma and ExPEC, positioning it at the forefront of genetic medicine
Read full SWOT analysis

CureVac NV Earnings Call Summary for Q3/2024

  • Q3 revenue soared to €493.9M, driven by €1.45B GSK licensing deal; strong cash position of €551M reported
  • Strategic shift to oncology and infectious diseases; 30% workforce reduction planned to enhance efficiency
  • Advancing mRNA cancer vaccines; new program for urinary tract infections shows promise in preclinical studies
  • Operating expenses expected to rise 30%+ in 2024; aim to decrease by over 30% starting 2025
  • Axel Malkomes appointed as new CFO; U.S. court case scheduled for March 2025 regarding ongoing litigation
Last Updated: 11/13/2024, 04:54 AM
Read Full Transcript

Earnings

Latest Release
Apr 29, 2026
EPS / Forecast
-- / -0.09
Revenue / Forecast
-- / 13.35M
EPS Revisions
Last 90 days

Compare CVAC to Peers and Sector

Metrics to compare
CVAC
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x−0.2x
PEG Ratio
0.000.000.00
Price / Book
0.0x0.0x2.6x
Price / LTM Sales
0.0x0.0x2.7x
Upside (Analyst Target)
-0.0%72.2%
Fair Value Upside
Unlock0.0%12.4%Unlock

People Also Watch

15.07
BMNR
-2.59%
3.200
ACHR
-0.93%
44.91
CRWV
-6.10%
2.910
SOUN
-3.32%
81.38
BNTX
-2.26%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.